Auriga Reiterates a 'Buy' on 3SBio (SSRX); Raising PT on Strong Q4 and Promising JV
Tweet
Share
E-mailGet Alerts SSRX Hot Sheet
Price: $16.59 --0%
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
Auriga reiterates a 'Buy' on 3SBio (NASDAQ: SSRX) price target raised to $16.00.
Auriga analyst said, "3SBio reported after the market close on 3/8/2012, and beat consensus on both revenue and EPS. Revenue was $22.2 million vs. consensus of $20.2 million and our estimate of $19.7 million. EPS was $0.16 vs. consensus and our estimate of $0.13. The increase is primarily due to increased revenue of the company's lead product EPIAO (generic Epogen product for anemia). 2012 guidance appears conservative. Management guided 2012 revenue in the range of $99-$108 million, implying 15%-25% top line growth. For the past two years, the lead product EPIAO has been growing at 32-34% annualized rate. We believe that the EPO market in China is still early in development and it is likely that a 30+% annual growth rate can be maintained for the foreseeable future. To reach the top end of the forecast, we modeled a conservative 21% growth rate. For TPIAO, we also modeled a yoy growth rate of 29% which falls in line with the past growth trajectory."
For an analyst ratings summary and ratings history on 3SBio click here. For more ratings news on 3SBio click here.
Shares of 3SBio closed at $14.19 yesterday.
Auriga analyst said, "3SBio reported after the market close on 3/8/2012, and beat consensus on both revenue and EPS. Revenue was $22.2 million vs. consensus of $20.2 million and our estimate of $19.7 million. EPS was $0.16 vs. consensus and our estimate of $0.13. The increase is primarily due to increased revenue of the company's lead product EPIAO (generic Epogen product for anemia). 2012 guidance appears conservative. Management guided 2012 revenue in the range of $99-$108 million, implying 15%-25% top line growth. For the past two years, the lead product EPIAO has been growing at 32-34% annualized rate. We believe that the EPO market in China is still early in development and it is likely that a 30+% annual growth rate can be maintained for the foreseeable future. To reach the top end of the forecast, we modeled a conservative 21% growth rate. For TPIAO, we also modeled a yoy growth rate of 29% which falls in line with the past growth trajectory."
For an analyst ratings summary and ratings history on 3SBio click here. For more ratings news on 3SBio click here.
Shares of 3SBio closed at $14.19 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alpine Income Property Trust (PINE) PT Lowered to $18 at Jones Trading
- Iluka Resources Ltd (ILU:AU) (ILKAF) PT Raised to AUD7.40 at Canaccord Genuity
- Banner Corporation (BANR) PT Lowered to $51 at Piper Sandler
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
